Alembic Pharmaceuticals Ltd
|
|
- Lizbeth Collins
- 5 years ago
- Views:
Transcription
1 Pharmaceuticals Ltd Investor Presentation January-2018
2 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual
3 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited, to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment and governmental laws and regulations affecting domestic and foreign operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited, to inability to build production capacity to meet demand, unavailability of raw materials and failure to gain market acceptance.
4 Milestones Established by Amin family FDA approves API facility Acquired Dabur s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility Pharmaceuticals business demerged from APL listed. Rhizen JV for NCE research Launched first NDA with a partner Commenced filing in EU, Australia and Brazil Mami JV in Algeria Launched Aripiprazole on day-1. Established US front-end: transition to direct marketing Aleor JV with Orbicular 2017 Acquisition of Orit Laboratories LLC, USA
5 Highlights Q3FY18 Financial Highlights India Formulations Gr% Particular (Rs bn) Q3FY17 Q3FY18 Gr% Rs 3.07bn Rs 3.49bn 14% Net Sales % EBITDA Pre R&D % 55% 54% Specialty 10% Margin % 34% 33% R&D % Acute 16% R&D % 16% 12% EBITDA Post R&D % 36% 36% Margin % 19% 22% Net Profit % 9% 10% Q3FY17 Q3FY18 Vet 23% International Generics Gr% API Business Rs 3.03bn Rs 3.11bn 3% Rs 1.67bn Rs 1.80bn 75% 76% US 4% ANDA Filings : 4 Approvals: 1 8% 2 DMF applications filed 25% 24% Non US -2% Q3FY17 Q3FY18 Aleor JV Filings : 1 Q3FY17 Q3FY18
6 Highlights 9MFY18 Financial Highlights India Formulations Gr% Particular (Rs bn) 9MFY17 9MFY18 Gr% Rs 9.70bn Rs 9.70bn Net Sales % Specialty -1% EBITDA Pre R&D % 58% 57% Margin % 33% 33% R&D % Acute 1% R&D % 13% 13% EBITDA Post R&D % 33% 33% Margin % 20% 21% Net Profit % 9% 10% 9MFY17 9MFY18 Vet 6% International Generics Gr% API Business Rs 9.64bn Rs 8.54bn -11% Rs 4.59bn -1% Rs 4.53bn 74% 74% US -11% ANDA Filings : 13 Approvals: 11 9 DMF applications filed 26% 26% Non US -11% 9MFY17 9MFY18 Aleor JV Filings : 1 9MFY17 9MFY18
7 Highlights FY17 Financial Highlights India Formulations Gr% Particular (Rs bn) FY16 FY17 Gr% Rs 11.76bn Rs 12.55bn 7% Net Sales % Specialty 13% EBITDA Pre R&D % 54% 58% Margin % 42% 33% R&D % Acute -4% R&D % 10% 14% EBITDA Post R&D % 37% 33% Margin % 32% 20% Net Profit % 9% 9% FY16 FY17 Vet 16% International Generics Rs 14.61bn Rs 12.36bn Gr% -15% API Business 22% Rs 6.40bn 84% 74% US -25% ANDA Filings :20 Approvals: 4 Rs 5.25bn 7 DMF applications filed 16% 26% Non US 37% FY16 FY17 FY16 FY17
8 Business Key Numbers (Rs bn) Capex 4.8 HQ, Vadodara R&D: Formulation: Vadodara and Hyderabad API: Biocentre: 1.3 Vadodara and Hyderabad (Peptides) Vadodara 150 beds FY15 FY16 FY17 Sales EBITDA R&D Total 800 R&D employees strength Branded, Mumbai India Ex-India Manufacturing: Generics, Vadodara International Generics API Formulation: Oral Solids, Panelav (Mar16)* Oncology OSD, Panelav Derma JV, Karkhadi API: Oncology Injectables, Panelav (H1FY19) General Injectables, Karkhadi (H1FY19) New Oral Solids, Jarod (H2FY19) Sikkim, India market Panelav (Jun16)*, Karkhadi (Apr15)* * Last inspection
9 International Generics Sales (Rs bn) 14.6 CAGR 42% 12.4 ANDA Filed Filings: 119 Approval: 70* * Incl 9 tentative FY13 FY14 FY15 FY16 FY17 FY13 FY14 FY15 FY16 FY17 R&D Spend (Rs bn) Milestones and Update Acquired US based Orit Laboratories LLC 7 Approved ANDAs and 4 ANDAs Pending approval R&D% 3.2 US front-end in place, 38 products already launched (including relaunches) new products launch and 1 relaunch in USA in 9MFY new launches planned in FY19 FY13 FY14 FY15 FY16 FY17 Ex-US driven by partnerships
10 India Formulations Sales (Rs bn) CAGR 9% Marketing Organisation marketing team 17 marketing divisions 170 products, 15% of products in NLEM FY13 FY14 FY15 FY16 FY17 Split CAGR% Key Achievements % of Domestic Formulations FY13 FY14 FY15 FY16 FY17 6% 21% Successful key new launches Tellzy, Rekool, Gestofit, Ovigyn D, Rosave, Richar Last 5 year new launches cover 2% of market share and contribute 19% of sales. 90% new launches in specialty 5 brands in top 300 Azithral, Althrocin, Wikoryl, Gestofit, Roxid Specialty Acute
11 -wise Performance Q3FY18 Q3 FY 2018 Q3 FY 2017 Market Share (PRIM) Market Share (PRIM) Cardiology Anti Diabetic Gynaecology Gastrology Dermatological Orthopaedic Ophthalmology Nephro / Uro Anti Infective Cold & Cough (Source : ORG DEC 2017)
12 -wise Performance 9MFY18 9M FY M FY 2017 Market Share (PRIM) Market Share (PRIM) Cardiology Anti Diabetic Gynaecology Gastrology Dermatological Orthopaedic Ophthalmology Nephro / Uro Anti Infective Cold & Cough (Source : ORG DEC 2017)
13 -wise Performance MAT DEC 17 MAT DEC 2017 MAT DEC 2016 Market Share Market Share Cardiology Anti Diabetic Gynaecology Gastrology Dermatological Orthopaedic Ophthalmology Nephro / Uro Anti Infective Cold & Cough (Source : ORG DEC 2017)
14 Strategy R&D Pipeline drivers Dosage Form FY14 FY18 Oral Solids Injectables Oncology Dermatology Opthalmology Inhalation Biologics NCEs R&D: US: India: Rapidly expand breadth and quality of pipeline Doubled internal OSD grid. injectable, dermatology ophthalmology and oncology. Expanded grid 5 fold Partnerships to gain time Build manufacturing capacities rapidly, use CMOs > 80% of R&D spend towards US market On ground presence. Focus on quality and supply chain Emphasis on specialty segment Market share in identified therapy-important molecules Enablers Pipeline Skills People: Renewed focus on HR Talent acquisition and retention High Mix of high-risk and low-risk projects. Process: Simple, clear structures Clear goals and empowerment Focus on compliance De-risk with systems Close monitoring Low Low High Building skill sets organically and inorganically. Risk
15 Financials 5 years Sales Rs 15.3bn Rs 31.3bn CAGR% 20% Sales (Rs bn) CAGR 20% 23% 20% API 16% % 40% India 9% % 40% International 42% FY13 FY17 FY13 FY14 FY15 FY16 FY17 EBITDA (Rs bn) 32% Net Profit (Rs bn) 23% 17% 19% 19% Margins% % 11% Margins% 13% 14% % FY13 FY14 FY15 FY16 FY17 FY13 FY14 FY15 FY16 FY17
16 Latest Shareholding Pattern % of Total Shareholding Promoter & Promoter group FI/FII/MF 73 Public Market capitalisation (Rs bn) CAGR 38% Total paid-up share capital Total number of shares O/S mn mn No. of shareholders >50 K FY13 FY14 FY15 FY16 FY17 9MFY18
17 THANK YOU
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation July-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationAlembic Pharmaceuticals Ltd. Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation October-2016 Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationAlembic Pharmaceuticals Limited Investors Update Q3FY12
Alembic Pharmaceuticals Limited Investors Update Q3FY12 Quarter ended 31 st December 2011 Net sales up 15% at Rs 382 crores against Rs. 331 crores in corresponding quarter last year Domestic formulations
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationAlembic Pharmaceuticals Limited Consolidated Results for Quarter / Year ended
For Immediate Release Alembic Pharmaceuticals Limited Consolidated Results for Quarter / Year ended 31.03.2011 Editors Synopsis For the quarter net sales up 30% at Rs 297.73 crores against Rs. 228.77 crores
More informationPRESS MEET Q4 & FY14. Dr. Reddy s Laboratories Limited May 13, Dr. Reddy's Laboratories Limited. All Rights Reserved.
Dr. Reddy s Laboratories Limited May 13, 2014 Q4 FY 14 Business Highlights Sales Gross Profit 3,481 Cr 4.2 % 57.2 % 18 % YoYGr% to sales YoYGr% R & D Adj. EBITDA 11.4 % 71 % 22.8 % 2 %* to sales YoYGr%
More informationQ3 FY17-18 EARNINGS PRESENTATION. 7 th February 2018
Q3 FY17-18 EARNINGS PRESENTATION 7 th February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationQ4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017
Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationmore ALEMBIC PHARMACEUTICALS LIMITED ANNUAL REPORT,
+ + + + + more + + ALEMBIC PHARMACEUTICALS LIMITED ANNUAL REPORT, 2016-17 In the pharmaceutical space, your past efforts determine your present standing and your present strategy your future progress.
More informationAlembic Pharmaceuticals Ltd 25 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Alembic Pharmaceuticals Ltd 25 th September, 2012 CMP Target Price Rs.70.85 Rs.90.00 Alembic Pharma continues to maintain its market share
More informationQ2 FY18-19 EARNINGS PRESENTATION
Q2 FY18-19 EARNINGS PRESENTATION 12 th November 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationQ4 FY17-18 EARNINGS PRESENTATION
Q4 FY17-18 EARNINGS PRESENTATION 28 th May 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationPress Presentation Q1 FY19
1 July 26, 2018 Q1 FY19 Press Meet Press Presentation Q1 FY19 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationQ2 FY18 Investor Presentation
Q2 FY18 Investor Presentation Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are
More informationInvestor Presentation 2 nd Qtr. - FY 2018
Investor Presentation 2 nd Qtr. - FY 2018 31 st October, 2017 1 of 33 India Disclosure Index 2017 Ajanta s Ranking in Next 100 Listed Companies (Based on Market Cap) 1 st 2 nd 3 rd Voluntary Disclosure
More informationPress Meet Q3 FY16. February 9, Dr. Reddy s Laboratories Limited.
Press Meet Q3 FY16 February 9, 2016 Dr. Reddy s Laboratories Limited. Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More informationCadila Healthcare Ltd.
Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:
More informationFinancial Results Quarter Ended December 31, 2015
Financial Results Quarter Ended December 31, 2015 Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives,
More informationPress Presentation Q4 18 & FY18
1 May 22, 2018 Q4 FY18 Press Meet Press Presentation Q4 18 & FY18 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationINVESTOR COMMUNICATION Q2FY18 & H1FY18
Sales Q2FY18 : Rs.1,022 crore vs Rs 1,065 crore in PY H1FY18 : Rs. 1,913 crore vs Rs 2,156 crore in PY EBITDA before R&D Q2FY18 : Rs. 84 crore vs Rs 199 crore in PY H1FY18 : Rs 77 crore vs Rs 392 crore
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationPress Presentation- Q3 FY17. February 4th, 2017
Press Presentation- Q3 FY17 February 4th, 2017 Q3 Dr. FY17 Reddy s Press meet Laboratories Limited 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationInvestor Presentation
Aurobindo Pharma Limited Investor Presentation Investor Presentation August 2015 May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including
More informationSource: Company Data; PL Research
US generics, low RM costs lead to margin surprise May 08, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs990 Target Price Rs1,156 Implied Upside 16.8% Sensex 22,324 Nifty
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationDr. Reddy s Q4 and FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationFinancial Results Analysis Quarter & 9 Months Ended December 31, 2011
Financial Results Analysis Quarter & 9 Months Ended December 31, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More informationSetting the pace. Shaping the future. Alembic Pharmaceuticals Limited Annual Report
Setting the pace. Shaping the future. Alembic Pharmaceuticals Limited Annual Report 2014-15 Board of Directors Mr. K. G. Ramanathan Independent Director Mr. Paresh Saraiya Independent Director Mr. Pranav
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationLupin Limited Corporate Presentation. May 2009
Lupin Limited Corporate Presentation May 2009 Corporate Highlights Eleventh successive quarter of growth in sales and profits. Growth has been secular across SBUs and regions Particularly strong in US,EU,
More informationJUBILANT LIFE SCIENCES Q4/FY2017 RESULTS
PRESS RELEASE Noida, Tuesday, May 23, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4/FY2017 RESULTS JUBILANT REPORTS
More informationViews on the Generics Market
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul, Turkey 15 th June 2007 Safe Harbor Except for
More informationDr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012
Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet February 03, 2012 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationDr. Reddy s Q1 FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationAurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months
Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 Nov-17 Mar-18 Jul-18 Nov-18 2QFY2019 Result Update Pharmaceutical November 17, 2018 Aurobindo Pharma Performance Highlights Y/E march (` cr) 2QFY19 1QFY19 % chg
More informationUnichem Laboratories Ltd.
Unichem Laboratories Ltd. May 31, 2013 BSE Code: 506690 NSE Code: UNICHEMLAB Reuters Code: UNLB.NS Bloomberg Code: UL:IN Unichem Laboratories Ltd is an international, integrated, specialty pharmaceutical
More informationASX Announcement MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE
23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE Revenue of $243.3m, a decrease of 17% on 1HFY17 Adjusted EBITDA of $70.2m, down 36% on 1HFY17 Reported EBITDA of $23.0m, down 82% on 1HFY17
More informationFinancial Results Analysis Quarter & Half Year Ended September 30, 2011
Financial Results Analysis Quarter & Half Year Ended September 30, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationBird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
More informationDr. Reddy s Q4 & FY15 Financial Results
PRESS RELEASE.. Dr. Reddy s Q4 & FY15 Financial Results Q4 FY15 Revenues at 38.7 billion FY15 Revenues at 148.2 billion (YoY growth of 11%) Q4 FY15 EBITDA at 8.1 billion (21% of revenues) (YoY growth of
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationDr. Reddy s Q1 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15. Revenue figures
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15 Revenue figures (` In Lacs) Unaudited Audited Particulars July 14 Sept. 14 Quarter Ended Apr. 14 Jun. 14 July 13 Sept.
More informationNATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza,
(? AUROBINDO Date: November 12, 2018 To To NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza, 25 th floor, Dalal Street, Sandra Kurla Complex, Sandra (E), MUMBAI
More informationSource: Company Data; PL Research
Result disappoints; Competition catching up in key drugs May 14, 2015 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs1,632 Target Price Rs1,823 Implied Upside 11.7% Sensex
More informationHardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy
BSE Sensex S&P CNX 19,990 6,069 Bloomberg LPC IN Equity Shares (m) 447.6 M.Cap. (INR b)/(usd b) 324.5/6.0 52-Week Range (INR) 739/507 1,6,12 Rel. Perf. (%) 9/18/13 Financials & Valuation (INR b) Y/E March
More informationJUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS
PRESS RELEASE Noida, Saturday, Oct 28, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS The Board
More informationACETO Corporation. June 8, 2016
NASDAQ:ACET ACETO Corporation Jefferies Healthcare Conference June 8, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by
More informationKey estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,
: price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn
More informationSales EBITDA EBITDA PAT KEY INDICATORS. before R&D. Q2FY19 : Rs.1,125 crore vs Rs.1,022 crore in PY. H1FY19 : Rs.2,133 crore vs Rs.
Sales Q2FY19 : Rs.1,125 crore vs Rs.1,022 crore in PY H1FY19 : Rs.2,133 crore vs Rs.1,913 crore in PY EBITDA before R&D Q2FY19 : Rs.134 crore vs Rs.85 crore in PY H1FY19: Rs.224 crore vs Rs.78 crore in
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationWOCKHARDT LIMITED MANAGEMENT DISCUSSION AND ANALYSIS REPORT
MANAGEMENT DISCUSSION AND ANALYSIS REPORT 2009 was indeed a challenging year for the Company. The predominant theme in 2009 was and will continue to be More and More with Less and Less. Strengthening business
More informationLupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart
2QFY2017 Result Update Pharmaceutical November 11, 2016 Lupin Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg qoq 2QFY2016 % chg yoy Net sales 4,212 4,316 (2.4) 3,193 31.9 Other income
More informationDr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationDr. Reddy s Q4 and FY18 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationWockhardt Limited. Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationQ4 18 and FY18 Investor Presentation
Q4 18 and FY18 Investor Presentation Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More informationIronwood 4Q 2017 and Full-Year 2017 Investor Update
A COMMERCIAL BIOTECHNOLOGY COMPANY Ironwood 4Q 2017 and Full-Year 2017 Investor Update February 15, 2018 Introduction Meredith Kaya Vice President, Investor Relations and Corporate Communications Safe
More informationDr Reddy s Laboratories Ltd. Q1 FY05 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 04 Branded Formulations
More informationDr. Reddy s Q3 and 9M FY18 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CIN: L85195TG1984PLC004507 INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph:
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationIndian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
More informationAjcon s Xpress idea: Dr. Reddy s Ltd. (DRRD: IN) - BUY 5 th Jan, 2015
Ajcon s Xpress idea: Dr. Reddy s Ltd. (DRRD: IN) - BUY 5 th Jan, 2015 CMP: 3,146 Target: Rs. 3,800 Upside: 21% Market Cap: Rs. 537 bn FV: Rs. 5 About the Company Dr. Reddy s Laboratories Ltd. is an integrated
More informationAurobindo Pharma Ltd Q1 FY18-19 Financial Results Q1 Q1
NEWS RELEASE 9 th August 2018, Hyderabad, India Consolidated financial results Q1FY18-19 Aurobindo Pharma Ltd Q1 FY18-19 Financial Results Amount in INR Cr Q1 Q1 Q4 FY18-19 FY17-18 FY17-18 Revenue from
More informationFY2017 FY2018E FY2019E
Jul-12 Dec-12 May-13 Oct-13 Mar-14 Aug-14 Jan-15 Jun-15 Nov-15 Apr-16 Sep-16 Feb-17 Jul-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Lupin Performance Highlights Y/E March (`cr) 2QFY2018
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationDear Fellow Shareholders On behalf of the Board of Directors, I take pleasure in welcoming all of you to the 17 th AGM of your company.
Text of the speech delivered by Mr. Dilip Shanghvi, Chairman and Managing Director of the Sun Pharmaceutical Industries Ltd., at the 17 th Annual general meeting of the company held on Sept 11, 2009 in
More informationADD. Lupin (LPC) Pharmaceuticals
Lupin (LPC) Pharmaceuticals Margin surprise drives beat. Lupin delivered a strong quarter on both sales and EBITDA margin fronts. Multiple launches in US were the key driver for the sales beat. Margin
More informationIndian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route
Aurum Equity Partners LLP Aurum Insights Pharmaceuticals October 2014 Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route Read more
More informationDr. Reddy s Laboratories
Mar-12 Aug-12 Jan-13 Jun-13 Nov-13 Apr-14 Sep-14 Feb-15 Jul-15 Dec-15 May-16 Oct-16 Mar-17 Aug-17 2QFY2018 Result Update Pharmaceutical November 24, 2017 Dr. Reddy s Laboratories Performance Highlights
More informationDISCUSSION SUMMARY. Q1 FY15 Results Highlights About Us Q1 FY15 Consolidated Financials 14. Business Strategy & Outlook 17
DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q1 FY15 QUARTERLY INVESTOR UPDATE AUGUST 2014 DISCUSSION SUMMARY Q1 FY15 Results Highlights 04 08 About Us 09 13 Q1 FY15 Consolidated Financials 14 Business
More informationACETO Corporation NASDAQ: ACET. Update May 2018
ACETO Corporation NASDAQ: ACET Update May 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can be identified
More informationAurobindo Pharma Ltd Q3 FY17-18 Financial Results Q3 Q3
NEWS RELEASE 7 th February 2018, Hyderabad, India Consolidated financial results Q3FY17-18 Aurobindo Pharma Ltd Q3 FY17-18 Financial Results Amount in INR Cr Q3 Q3 9M 9M FY17-18 FY16-17 FY17-18 FY16-17
More informationAurobindo Pharma Limited. Investor Presentation
Aurobindo Pharma Limited Investor Presentation May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation, statements
More informationInstitutional Equities
1QFY19 Result Update Institutional Equities Aurobindo Pharma 13 August 2018 Reuters: ARBP.NS; Bloomberg: ARBP IN One-offs Impact Margin Aurobindo Pharma (APL) reported 1QFY19 revenues of Rs42,503mn which
More informationINVESTOR PRESENTATION. November 2015
INVESTOR PRESENTATION November 2015 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the implementation
More informationInvestor Presentation Q2FY
Investor Presentation Q2FY19 05-11-2018 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking
More informationAcrux (ASX: ACR) Annual General Meeting. 10 November, 2016
Acrux (ASX: ACR) Annual General Meeting 10 November, 2016 1 Introduction: Ross Dobinson Non-Executive Chairman 2 Company review: Michael Kotsanis CEO & Managing Director 3 Forward looking statements This
More informationChief Executive Officer
Said Darwazah Chief Executive Officer 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m 85 8 75 BRANDED + 9.6% $37.9 m INJECTABLES + 23.3% $36.7 m GENERICS
More informationWockhardt Limited. Investor Presentation By Dr. Murtaza Khorakiwala Managing Director. February 2013
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director February 2013 Safe Harbor Statement Except for historical information contained herein, statements in this communication,
More informationQ1 19 Presentation for the Investors August 9, 2018
Q1 19 Presentation for the Investors August 9, 2018 DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words
More informationSun Pharma BUY. Performance Highlights. `683 Target Price `847 CMP. 2QFY2017 Result Update Pharmaceutical. Investment Period 12 months
2QFY2017 Result Update Pharmaceutical November 17, 2016 Sun Pharma Performance Highlights (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 7,764 8,007 (3.0) 6,858 13.2 Other income 621
More information